☆ 4.5 Review

Pembrolizumab versus paclitaxel for previously treated, advanced gastro-esophageal junction cancer: A systematic review and meta-analysis of randomized clinical trials

MEDICINE (2022)

Related references

Note: Only part of the references are listed.

Article Oncology

Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial

Charles S. Fuchs et al.

Summary: In this long-term analysis, second-line pembrolizumab did not significantly improve overall survival but was associated with higher 24-month OS rates than paclitaxel in the CPS>=1 population. Pembrolizumab also increased overall survival benefit with PD-L1 enrichment among patients with PD-L1-positive gastric/GEJ cancer and led to fewer treatment-related adverse events (TRAEs) compared to paclitaxel.

GASTRIC CANCER (2022)

Add to Collection

Article Medicine, General & Internal

The current and future incidence and mortality of gastric cancer in 185 countries, 2020-40: A population-based modelling study

Eileen Morgan et al.

Summary: This study analyzed the global patterns of gastric cancer in 2020 and predicted the burden for 2040. The incidence and mortality rates of gastric cancer varied by sex, country, and level of human development. Eastern Asia had the highest rates, while Africa had the lowest. The predicted burden of gastric cancer is expected to increase by 2040.

ECLINICALMEDICINE (2022)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Medicine, General & Internal

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

Yelena Y. Janjigian et al.

Summary: Nivolumab plus chemotherapy showed superior overall survival and progression-free survival compared to chemotherapy alone in previously untreated patients with advanced gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma, indicating it as a new standard first-line treatment option with acceptable safety profile.

LANCET (2021)

Add to Collection

Article Oncology

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021

Feng-Hua Wang et al.

Summary: Gastric cancer patients from Eastern and Western countries exhibit different characteristics, and the Chinese Society of Clinical Oncology has developed guidelines that take into account regional differences and aim to provide personalized recommendations. The 2021 guidelines cover various aspects of gastric cancer diagnosis and treatment, integrating research data from both China and overseas to offer more relevant recommendations.

CANCER COMMUNICATIONS (2021)

Add to Collection

Article Oncology

The association of molecular biomarkers with efficacy of pembrolizumab versus paclitaxel in patients with gastric cancer (GC) from KEYNOTE-061.

Charles S. Fuchs et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Multidisciplinary Sciences

Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry

Almudena Cotes Sanchis et al.

PLOS ONE (2020)

Add to Collection

Meeting Abstract Oncology

Efficacy and safety of pembrolizumab (pembro) alone or in combination with chemotherapy (chemo) in patients (pts) with advanced gastric or gastroesophageal (G/GEJ) cancer: Long-term follow up from KEYNOTE-059.

Zev A. Wainberg et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Article Gastroenterology & Hepatology

Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial

Yasuhide Yamada et al.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2019)

Add to Collection

Review Oncology

First-line systemic therapy for advanced gastric cancer: a systematic review and network meta-analysis

Ji Cheng et al.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kohei Shitara et al.

LANCET (2018)

Add to Collection

Article Oncology

Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Phase 2 Clinical KEYNOTE-059 Trial

Charles S. Fuchs et al.

JAMA ONCOLOGY (2018)

Add to Collection

Article Oncology

Examining the gastric cancer survival gap between Asians and whites in the United States

Hongbin Jin et al.

GASTRIC CANCER (2017)

Add to Collection

Review Oncology

Survival after failure of first-line chemotherapy in advanced gastric cancer patients: differences between Japan and the rest of the world

Atsuo Takashima et al.

JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2017)

Add to Collection

Article Oncology

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

Kei Muro et al.

LANCET ONCOLOGY (2016)

Add to Collection

Article Oncology

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

Hansjochen Wilke et al.

LANCET ONCOLOGY (2014)

Add to Collection

© Peeref 2019-2024. All rights reserved.